Cite
HARVARD Citation
Chen, K. et al. (2016). Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC cancer. 16 (1), pp. 1-8. [Online].